$CSBR

CHAMPIONS ONCOLOGY, INC.

CIK:0000771856|SEC Filings

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2026	Jul. 31, 2025
Income Statement [Abstract]
Revenue, Product and Service [Extensible List]	Service [Member]	Service [Member]
Oncology revenue	$ 15,232	$ 13,995
Costs and operating expenses:
Cost, Product and Service [Extensible List]	Service [Member]	Service [Member]
Cost of oncology revenue	$ 7,534	$ 7,995
Research and development	2,344	2,082
Sales and marketing	3,090	1,855
General and administrative	2,673	2,570
Loss on disposal of equipment	0	20
Total costs and operating expenses	15,641	14,522
Loss from operations	(409)	(527)
Other income (expense), net	(6)	75
Loss before provision for income taxes	(415)	(452)
Provision for income taxes	11	14
Net income (loss) attributable to Company's common shares	$ (426)	$ (466)
Net loss per common share outstanding
basic (in dollars per share)	$ (0.03)	$ (0.03)
Weighted average common shares outstanding
basic (in shares)	13,897,535	13,788,414

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2026	Jul. 31, 2025
Operating activities:
Net loss	$ (426)	$ (466)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation	766	208
Depreciation and amortization expense	314	358
Loss on disposal of equipment	0	20
Operating lease right-of use assets	268	310
Non-cash interest	17	0
Allowance and estimated credit losses	(10)	(29)
Changes in operating assets and liabilities:
Accounts receivable	(414)	1,759
Prepaid expenses and other current assets	(163)	154
Other long term assets	11	0
Accounts payable	(1,425)	411
Accrued liabilities	83	(755)
Operating lease liabilities	(237)	(356)
Deferred revenue	724	(1,014)
Net cash (used in) provided by operating activities	(492)	600
Investing activities:
Purchase of property and equipment	(55)	(46)
Net cash used in investing activities	(55)	(46)
Financing activities:
Proceeds from exercise of options	52	24
Finance lease payments	(19)	(38)
Net cash provided by (used in) financing activities	33	(14)
(Decrease) Increase in cash	(514)	540
Cash at beginning of period	4,872	9,785
Cash at end of period	4,358	10,325
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities	6,246	0
Equipment acquired under vendor financing arrangements	412	0
Additional equipment purchased in accounts payable	$ 125	$ 286

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jul. 31, 2026	Apr. 30, 2026
Current assets:
Cash and cash equivalents	$ 4,358	$ 4,872
Accounts receivable, net	13,602	13,178
Prepaid expenses and other current assets	1,332	1,169
Total current assets	19,292	19,219
Operating lease right-of-use assets, net	9,675	3,697
Property and equipment, net	3,787	3,526
Other long-term assets	201	212
Goodwill	335	335
Total assets	33,290	26,989
Current liabilities:
Accounts payable	5,632	6,903
Accrued liabilities	2,676	2,592
Current portion of operating lease liabilities	635	1,520
Other current liability	234	79
Deferred revenue	9,552	8,828
Total current liabilities	18,729	19,922
Non-current operating lease liabilities	9,886	2,992
Other non-current liabilities	215	7
Total liabilities	28,830	22,921
Stockholders’ equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 14,038,902 and 14,007,159 shares issued; and 13,918,569 and 13,886,826 outstanding as of July 31, 2026 and April 30, 2026, respectively	14	14
Treasury stock, at cost	(708)	(708)
Additional paid-in capital	86,080	85,700
Accumulated deficit	(81,493)	(81,067)
Total stockholders’ equity attributable to Champions Oncology, Inc.	3,893	3,939
Non-controlling interest	567	129
Total stockholders' equity	4,460	4,068
Total liabilities and stockholders’ equity	$ 33,290	$ 26,989